45 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Inhibition of Histone Demethylases Offers a Novel and Promising Approach for the Treatment of Cancer and Other Diseases.
Therachem Research Medilab (India)
Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives.
Glaxosmithkline
Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors.
University of Oxford
Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives.
Glaxosmithkline
Identification of Jumonji AT-Rich Interactive Domain 1A Inhibitors and Their Effect on Cancer Cells.
Kyoto Prefectural University of Medicine
Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity.
Kyoto Prefectural University of Medicine
Inhibitor scaffold for the histone lysine demethylase KDM4C (JMJD2C).
University of Copenhagen
Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors.
Nagoya City University
Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors.
University of Oxford
Recent Advances with KDM4 Inhibitors and Potential Applications.
St. Jude Children'S Research Hospital
Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).
Hangzhou Normal University
Discovery of pyrazole derivatives as cellular active inhibitors of histone lysine specific demethylase 5B (KDM5B/JARID1B).
Zhengzhou University
Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies.
Genentech
Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor.
University of Oxford
Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities.
Sapienza University of Rome
Targeting lysine specific demethylase 4A (KDM4A) tandem TUDOR domain - A fragment based approach.
Abbvie
Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models.
Celgene Quanticel Research
Structure-activity studies of a macrocyclic peptide inhibitor of histone lysine demethylase 4A.
The University of Tokyo
From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.
Genentech
N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors
The Regents of The University of Michigan
Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors
Zhejiang Dtrm Biopharma
Steroidal 5a-reductase inhibitors using 4-androstenedione as substrate.
Metropolitan University-Xochimilco
Substituted furans as potent lipoxygenase inhibitors: Synthesis, in vitro and molecular docking studies.
Csir-Indian Institute of Chemical Biology
Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor.
Genentech
Roles of phosphate recognition in inositol 1,3,4,5,6-pentakisphosphate 2-kinase (IPK1) substrate binding and activation.
Mcgill University
A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate.
Whitehead Institute For Biomedical Research
Design, synthesis and biological evaluation of 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine derivatives as c-Met inhibitors.
Tianjin University of Science and Technology
5-HT3 receptor modulators, methods of making, and use thereof
Albany Molecular Research